Business
Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
– Announced FDA acceptance of NDA for lorundrostat in adults with hypertension; assigned PDUFA target date of December 22, 2026 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., March 12, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, tod
About this update from Mineralys Therapeutics, Inc.
[{"type":"image","alt":"Mineralys Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Mineralys Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":79,"url":"https://media.zenfs.com/en/globenewswire.com/7d27eb215a09ca1c260f3840d5c29c6c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5IxdnQXer2KOyJylmLI.pw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7d27eb215a09ca1c260f3840d5c29c6c","width":300,"height":79}},"lazy":false},{"type":"text","content":"– Announced FDA acceptance of NDA for lorundrostat in adults with hypertension; assigned PDUFA target date of December 22, 2026 –","length":135,"tagName":"p"},{"type":"text","content":"– Conference call today at 4:30 p.m. ET –","length":51,"tagName":"p"},{"type":"text","content":"RADNOR, Pa., March 12, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a corporate update.","length":453,"tagName":"p"},{"type":"text","content":"“Mineralys had a transformational year in 2025, defined by significant clinical progress and key regulatory milestones,” said Jon Congleton, Chief Executive Officer of Mineralys Therapeutics. “We successfully completed multiple clinical trials, with results published in JAMA and The New England Journal of Medicine, highlighting the potential of lorundrostat to benefit patients with inadequately controlled hypertension. We also ended the year with the submission of our first NDA for the treatment of hypertension in adults. The FDA’s acceptance of this application marked a significant milestone, and we look forward to working closely with the agency as lorundrostat advances toward potential approval and commercialization.”","length":730,"tagName":"p"},{"type":"text","content":"Recent Clinical Highlights and Upcoming Milestones ","length":50,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Lorundrostat New Drug Application (NDA) – Mineralys announced the U.S. Food and Drug Administr...